Literature DB >> 10667655

Primary tumors and mediastinal lymph nodes after neoadjuvant concurrent chemoradiotherapy of lung cancer: serial CT findings with pathologic correlation.

K S Lee1, Y M Shim, J Han, J Kim, Y C Ahn, K Park, K J Jung.   

Abstract

PURPOSE: The purpose of this work was to describe the changes of primary tumor and mediastinal lymph nodes on CT after neoadjuvant concurrent chemoradiotherapy and to correlate the CT findings with pathology.
METHOD: Twenty-one consecutive patients [N2 disease (n = 19) or resectable T4 and N2 disease (n = 2)] with non-small cell lung cancer underwent neoadjuvant concurrent chemoradiotherapy. Changes of primary tumor and mediastinal nodes before and after the therapy were assessed using CT. The CT findings were correlated with pathologic findings.
RESULTS: With neoadjuvant therapy, decrease in T stage was achieved in 9 of 21 (43%) patients on CT. On pathology, the remaining tumor consisted mostly of fibrosis and necrosis with little proportion of viable tumor cells (mean volume 17%, range 0-55%). Decrease in nodal stage was achieved in 14 of 21 (67%) patients on pathologic examination. Seven patients had cancer cells in mediastinal lymph nodes: in 6 of 9 (67%) patients with adenocarcinoma and 1 of 12 (8%) patients with squamous cell carcinoma (p = 0.016).
CONCLUSION: With neoadjuvant concurrent chemoradiotherapy, the remaining tumor consists mostly of fibrosis or necrosis. Decreased nodal stage on pathology is achieved especially in patients with N2 disease of squamous cell carcinoma. The CT findings of the tumor and mediastinal nodes are not helpful in predicting the pathology after the therapy.

Entities:  

Mesh:

Year:  2000        PMID: 10667655     DOI: 10.1097/00004728-200001000-00007

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  5 in total

1.  Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer.

Authors:  Yuka Yamamoto; Yoshihiro Nishiyama; Toshihide Monden; Yasuhiro Sasakawa; Motoomi Ohkawa; Masashi Gotoh; Kotaro Kameyama; Reiji Haba
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-12       Impact factor: 9.236

Review 2.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

Review 3.  Positron emission tomography in lung cancer.

Authors:  Hiroaki Nomori; Yasuomi Ohba; Kentaro Yoshimoto; Hidekatsu Shibata; Kenji Shiraishi; Takeshi Mori
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-04-15

Review 4.  Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria.

Authors:  Andrea Caulo; Saeed Mirsadraee; Fabio Maggi; Lucia Leccisotti; Edwin J R van Beek; Lorenzo Bonomo
Journal:  Eur Radiol       Date:  2011-10-04       Impact factor: 5.315

5.  Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).

Authors:  E C J Phernambucq; B Biesma; E F Smit; M A Paul; A vd Tol; F M Schramel; R J Bolhuis; P E Postmus
Journal:  Br J Cancer       Date:  2006-08-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.